Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Scynexis announces FDA approval of Brexafemme as the first and only oral non-azole treatment for vaginal yeast infections

Written by | 6 Jun 2021

Scynexis Inc.,. announced that the FDA has approved Brexafemme(ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Brexafemme which represents… read more.

Lupin will partner with Endoceutics to commercialise Intrarosa for postmenopausal vulvovaginal atrophy in Canada

Written by | 20 Mar 2021

Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.